

polypeptide, wherein the N-terminus of the second portion is linked to the C-terminus of the first portion.

29. A nucleic acid molecule encoding the polypeptide construct of any preceding claim.

30. A vector comprising the nucleic acid molecule of claim **29**.

31. A composition comprising one or more than one independently selected polypeptide construct of any one of claims **1** to **30** and a pharmaceutically-acceptable carrier, diluent, or excipient.

32. A transgenic cellular host comprising the nucleic acid molecule of claim **29** or a vector of claim **30**.

33. The transgenic cellular host of claim **32**, further comprising a second nucleic acid molecule or a second vector encoding a second polypeptide construct different from the first polypeptide construct.

34. The use of a polypeptide construct according to any one of claims **1-28**, for treatment of a medical condition, disease or disorder.

35. The use according to claim **34**, wherein the medical condition, disease or disorder comprises cancer, ocular diseases, fibrotic diseases, or genetic disorders of connective tissue.

* * * * *